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We studied the inverse relationship between HER-2 and estrogen (ER) and progesterone (PR) receptors using HER-2 testing and correlated HER-2 status with histologic features in 3,655 unselected invasive breast carcinomas. Immunohistochemical analysis for ER, PR, and HER-2 and fluorescence in situ hybridization for HER-2 were performed. ER and PR expression were decreased significantly in HER-2+ tumors compared with HER-2-tumors (ER, 49.1% vs 78.17%; PR, 24.3% vs 53.13%). Even among HER-2+ tumors, the rate of ER or PR expression in high-grade tumors was significantly decreased compared with intermediategrade tumors. HER-2 was positive in 10.87% of grade 2 and 27.84% of grade 3 ductal carcinomas and negative in all grade 1 ductal carcinomas. HER-2 overexpression or amplification essentially was limited to grades 2 and 3 ductal carcinomas and correlated inversely with ER or PR expression. Although ER or PR expression is decreased in HER-2+ tumors, a substantial proportion of them still express ER or PR.
Breast cancer is the most common carcinoma in women and accounts for 22% of all female cancers, which is more than twice the prevalence of cancer in women at any other site. 1 Prognosis and management of breast cancer are influenced by the classic variables such as histologic type and grade, tumor size, lymph node status, status of hormonal receptors-estrogen receptor (ER) and progesterone receptor (PR)-of the tumor, and, more recently, HER-2 status. [2] [3] [4] [5] HER-2/neu, also known as c-erbB-2 (HER-2), a protooncogene located on chromosome 17, is amplified and/or the protein (HER-2) overexpressed in 15% to 25% of invasive breast carcinomas and is associated with a worse clinical outcome. [5] [6] [7] [8] In contrast, ER is expressed in 70% to 95% of invasive lobular carcinomas and in 70% to 80% of invasive ductal carcinomas, and PR is expressed in 60% to 70% of invasive breast carcinomas. 9, 10 Expression of ER and/or PR generally is associated with a better outcome. Survival and response to hormone therapy are most favorable among women with tumors positive for both ER and PR, intermediate for tumors discordant on receptor status, and least favorable for tumors negative for both. 2, 11, 12 The interrelationship of ER, PR, and HER-2 has come to have an important role in the management of breast cancer. It has been shown that patients with breast carcinoma overexpressing HER-2 do not respond to tamoxifen therapy. 5 Although HER-2 expression generally is inversely correlated with ER and PR expression, 13,14 the precise extent of its inverse relationship and its association with classic histologic prognostic indicators has not been studied systematically in a large series of cases.
In the present study, the standardized immunohistochemically based HercepTest (DAKO, Carpinteria, CA) and the PathVysion fluorescence in situ hybridization (FISH) assay (Vysis, Downers Grove, IL), 2 of the US Food and Drug Administration-approved methods for HER-2 testing, were used to examine the correlation between HER-2 status and expression of ER and PR and other histologic features in 3,655 cases of consecutive and unselected invasive breast carcinoma tested at our institution.
Materials and Methods
Case Selection
During a 3-year period, all invasive breast carcinomas, including primary and metastatic carcinomas, received in our department were included in the study. ER, PR, HER-2 immunohistochemical, and FISH analyses were performed successfully in a total of 3,655 tumors as part of the routine diagnostic workup. Histologic features of each tumor were obtained from pathology reports. All tests were performed in the Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, NY.
Histologic Examination
Histologic assessment of tumor type and grade were performed routinely on 4-to 5-µm-thick H&E-stained sections of formalin-fixed, paraffin-embedded tumors according to the criteria outlined in the World Health Organization Classification of Tumours. 15 Briefly, the nuclear grades of primary or metastatic ductal-type carcinomas were designated as follows: 1, small, regular uniform cells; 2, moderate increase in size and variability; 3, marked variation in size and shape. The architectural grades of ductal carcinomas were designated as follows: 1, well-developed (>75%) tubule formation; 2, moderate (10%-75%) tubule formation; 3, little or no (<10%) tubule formation. Because the architectural grade of most small metastatic tumors in the study could not be assessed reliably, the architectural grade of the corresponding primary tumors was used instead. Mitotic counts were not assessed in most of the tumors and therefore, were not included in the data analyses. Invasive lobular carcinomas included classic and pleomorphic types. Special-type carcinomas that were analyzed separately included pure mucinous, metaplastic, and adenoid cystic carcinomas.
Immunohistochemical Analysis
Tissue sections (4-5 µm thick) were used for all immunohistochemical analyses. The CONFIRM anti-ER (clone 6F11) and anti-PR (clone 16) monoclonal antibodies (Ventana, Tucson, AZ) were used for immunohistochemical analyses of ER and PR, respectively, performed on automated slide stainers (Ventana) according to the manufacturer's instructions. The ER and PR results were screened manually and interpreted as positive when more than 10% of tumor cells showed positive nuclear staining. HER-2 immunohistochemical analysis was performed using the HercepTest kit according to the manufacturer's instructions, and results were interpreted manually as follows: 0, no membrane staining; 1+, faint, partial membrane staining; 2+, weak complete membrane staining in more than 10% of invasive cancer cells; 3+, intense complete membrane staining in more than 10% of invasive cancer cells.
Fluorescence In Situ Hybridization
The PathVysion HER-2 probe kit (Vysis) was used for FISH analysis. In brief, the sections were baked overnight at 56°C, and the invasive carcinoma components were marked based on a corresponding H&E-stained section. Unstained sections were deparaffinized in CitriSolv (Vysis), dehydrated in 100% ethanol, and air dried. Slides then were subjected to protease digestion for 45 to 60 minutes, denatured, and hybridized with prewarmed probes for the HER-2 gene and chromosome 17 centromere (Her2/neu/CEP17 SG probe, Vysis) overnight at 37°C. They then were washed with posthybridization wash buffer at 72°C and counterstained with 4',6-diamidino-2-phenylindole (DAPI) in antifade solution, mounted, and scored. Slides first were scanned at low magnification (×100) using a DAPI filter to identify areas of optimal tissue digestion and nonoverlapping nuclei within the area of invasive carcinoma. Signal enumeration was performed under high magnification (×1,000). The number of chromosome 17 signals, HER-2 signals, and tumor nuclei scored were recorded for each tumor. At least 30 cells per tumor were scored. Tumors were interpreted as positive for HER-2 gene amplification when the ratio of HER-2 signals divided by chromosome 17 centromere signals was equal to or greater than 2.0.
Statistical Analyses
Statistical analyses were performed using the MannWhitney test and the χ 2 test. All reported P values are 2-tailed.
Results
The results of HER-2 immunohistochemical and FISH analyses on all tumors are summarized in ❚Table 1❚. HER-2 was overexpressed (immunohistochemical score of 2+ or 3+) in 26.89% of tumors (983/3,655) and amplified in 14.69% of tumors (537/3,655). When HER-2 positivity was defined as a tumor with a FISH ratio of 2.0 or more or an immunohistochemical score of 3+, most consistent with current clinical practice, the overall frequency of HER-2+ tumors was 15.65% (572/3,655).
The expression of ER or PR was decreased significantly in HER-2+ tumors in comparison with HER-2-tumors ❚Table 2❚. However, a substantial number of HER-2+ tumors still expressed ER or PR. When the data were analyzed further according to the level of HER-2 positivity based on immunohistochemical and FISH scores, we found that tumors exhibiting borderline HER-2 amplification (FISH ratio, 2.0-2.5) and low-level protein expression (immunohistochemical score, 0-2+) (total of 70 tumors in this study) showed rates of ER or PR expression similar to those of HER-2-tumors (ER, 73% vs 78%; PR, 47% vs 53%) (data not shown).
We also analyzed 2 other groups of tumors: (1) tumors exhibiting no HER-2 amplification (FISH ratio, <2.0) but high-level protein expression (immunohistochemical score, 3+) and (2) tumors exhibiting low-level HER-2 amplification (FISH ratio, 2.6-3.0) and low-level protein expression (immunohistochemical score, 0-2+). We found that these 2 groups of tumors showed rates of ER and PR expression similar to those of HER-2+ tumors (data not shown).
When HER-2 status was analyzed according to the histologic features of tumors, we found that HER-2 positivity virtually was limited to invasive breast carcinoma of the ductal type ❚Table 3❚. Among lobular carcinomas, HER-2 positivity was observed only in the pleomorphic type and not in classic-type tumors. The 3 HER-2+ pleomorphic lobular carcinomas showed 3+ immunohistochemical staining and FISH ratios of 3.0, 3.2, and 7.1, respectively. All 3 tumors were negative for E-cadherin by immunohistochemical analysis, confirming the lobular nature of the tumor cells ❚Image 1❚. None of the special-type carcinomas, primary or metastatic, showed HER-2 positivity. The rates of ER and PR expression in various tumor types are consistent with findings in the literature. 9, 10 As shown in ❚Table 4❚, HER-2 positivity was associated more strongly with higher histologic grade in primary and metastatic carcinomas. The rates of HER-2 positivity in metastatic tumors were similar to those of primary tumors, particularly in grade 3 (Table 4) .
Another notable but not unexpected finding, as shown in ❚Table 5❚, was that the vast majority of HER-2+ tumors were grade 3 tumors. Furthermore, the rate of ER and PR expression in nuclear grade 2 HER-2+ tumors was significantly higher than that in nuclear grade 3 tumors (ER and PR, P < .0001), demonstrating the inverse correlation of tumor nuclear grades and ER and PR expression even among HER-2+ tumors (Table 5 ). This difference also was seen when HER-2+ tumors were stratified based on architectural grade, although not as dramatically as in nuclear grade (Table 5) .
Discussion
Many investigators have studied the correlation of HER-2 with tumor grade. However, only a few studies have examined this relationship in large series of unselected breast carcinomas from a single institution using Food and Drug Administration-approved HER-2 testing methods. We performed this retrospective study to correlate HER-2 status with other routinely used tumor characteristics such as tumor type, tumor grade, and hormonal status in primary and metastatic breast carcinomas. Consistent with the most widely adapted clinical practice and the practice at our institution, we considered a tumor HER-2+ as being either FISH positive (ratio, ≥2.0) or scored immunohistochemically as 3+. Our data are consistent with those of other published studies in that ER and/or PR expression in general is correlated inversely with HER-2 overexpression or amplification. However, a substantial number of HER-2+ tumors still expressed ER (49.1%) or PR (24.3%). In most clinical practice, tumors with immunohistochemical scores of 0 or 1+ generally are considered HER-2-; therefore, they are not subjected to FISH testing. In the present study, 46 of the FISH+ tumors were negative by immunohistochemical analysis (0-1+). They constituted approximately 1.26% of all breast carcinomas in the present study. Biologically, these tumors indeed might behave more similarly to HER-2-tumors, but no data are available at present because patients with such tumors were not included in the clinical trials using trastuzumabbased therapy that have been published to date. 16, 17 Only prospective clinical trials may answer this question and ultimately define clinically relevant HER-2 positivity.
The correlation between HER-2 expression and tumor grade was studied in a large series of 1,210 cases by Rilke et al, 18 who found HER-2 overexpression rates of 3.9%, 20.4%, and 38.9% in tumors of grades 1, 2, and 3, respectively. Tsuda et al 19 found HER-2 amplification in 0% of grade 1 invasive ductal carcinomas, 10% of grade 2 ductal carcinomas, and 33% of grade 3 ductal carcinomas. More recently, Hoff et al 20 in a study of 388 cases found that HER-2 was amplified in fewer than 1% of grade 1, 17% of grade 2, and 23% of grade 3 tumors. Similarly, the present study showed HER-2 positivity in 0% of grade 1 invasive ductal carcinomas, including tubular carcinomas, approximately 10% of grade 2 ductal carcinomas, and almost 28% of grade 3 ductal carcinomas. Our data further demonstrated that only a minority of HER-2+ tumors were grade 2, and the rates of ER and PR expression in grade 2 tumors were significantly higher than those of grade 3 tumors, even when they all were HER-2+. These findings suggest that ductal carcinomas of intermediate grade also exhibit intermediate features in HER-2 overexpression and amplification and ER and PR expression.
The present study provided convincing evidence that HER-2 overexpression and amplification are limited essentially to invasive ductal carcinomas of intermediate to high grade. All pure mucinous carcinomas and grade 1 ductal carcinomas, including tubular carcinomas, were HER-2-. This might reflect the fact that these types of carcinomas in general carry a better prognosis and often are associated with ER and/or PR expression, whereas HER-2 overexpression and amplification generally are associated with aggressive tumors with a poor prognosis. In lobular carcinomas, HER-2 positivity was observed only in tumors of the pleomorphic type, which typically exhibit higher nuclear grades than classic lobular carcinomas. The 3 HER-2+ pleomorphic lobular carcinomas were scored immunohistochemically as 3+ and were FISH+. Our data support findings by others 20, 21 that classic lobular carcinoma does not show HER-2 overexpression or amplification. The 17 cases of metaplastic carcinomas and adenoid cystic carcinomas in the present study were negative for HER-2, ER, and PR. The pattern of HER-2 expression in metastatic carcinomas was similar to that in primary carcinomas. HER-2 overexpression and amplification were observed only in metastatic ductal carcinomas of grades 2 and 3, and the percentage of HER-2+ metastatic tumors also was similar to that of primary tumors of the same grade. However, we cannot conclude that metastatic tumors necessarily should exhibit the same HER-2 status as the primary counterparts because primary and metastatic tumors were not paired tumors from the same patient in this study and the primary tumors of most these metastases were not available for HER-2 testing.
To our knowledge, this is the largest series from a single institution to study HER-2 overexpression and amplification. The data provided conclusive evidence that HER-2 overexpression and amplification in invasive breast carcinomas virtually are limited to ductal carcinomas of grades 2 and 3. HER-2 overexpression and amplification also were found in pleomorphic lobular carcinomas. However, owing to the limited number of tumors diagnosed as such in this series, the accurate frequency of HER-2 positivity in pleomorphic lobular carcinomas cannot be determined. Finally, a fact worth emphasizing is that, although ER or PR expression was decreased significantly in HER-2+ tumors, a substantial proportion of these tumors still expressed ER (49.1%) or PR (24.3%).
